Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs ALLEGRA ALLERGY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine-induced vasodilation and bronchoconstriction by blocking the H1 receptor, thereby reducing allergic symptoms.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Relief of symptoms associated with seasonal allergic rhinitis (sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes),Treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (pruritus and hives)
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
Fexofenadine 180 mg orally once daily.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Terminal elimination half-life is 14.4 hours (range 8–16 hours) in healthy adults. In renal impairment, half-life may be prolonged; dose adjustment recommended for Cr Cl <30 m L/min.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Fexofenadine undergoes minimal hepatic metabolism; approximately 5% of the dose is metabolized by CYP3A4. It is primarily excreted unchanged in feces and urine.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primarily eliminated in feces (80%) and urine (approximately 15%) as unchanged drug. Biliary secretion contributes significantly.
38-45%, primarily bound to albumin.
60-70% bound to plasma proteins (mainly albumin and α1-acid glycoprotein).
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Steady-state volume of distribution (Vdss) is 5.4–16 L/kg (mean ~12 L/kg). The large Vd indicates extensive tissue distribution.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral bioavailability is approximately 30% (range 25–40%) due to first-pass metabolism. Bioavailability is reduced by fruit juices (e.g., grapefruit, apple, orange).
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
GFR 40-59 m L/min: 60 mg once daily; GFR 15-39 m L/min: 60 mg every other day; GFR <15 m L/min: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe (Child-Pugh C).
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Children 2-11 years: 30 mg orally twice daily; Children 12 years and older: same as adult dosing.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
No specific dose adjustment, but elderly patients may be more sensitive to anticholinergic effects; consider starting at lower end of dosing range. No renal adjustment needed if renal function normal.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
None.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Use with caution in patients with renal impairment (Cr Cl < 80 m L/min) as exposure is increased; consider dose adjustment.,Avoid concurrent use with aluminum- and magnesium-containing antacids, which reduce fexofenadine absorption by up to 40%.,Potential for QT prolongation at high doses (rare); caution in patients with pre-existing QT prolongation or electrolyte imbalances.,Not recommended for severe hepatic impairment due to lack of data.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to fexofenadine or any component of the formulation,End-stage renal disease (ESRD) with Cr Cl < 15 m L/min (use not recommended)
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Fruit juices (apple, orange, grapefruit) significantly decrease absorption of fexofenadine; avoid concurrent consumption. No other significant food interactions.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
Fexofenadine (ALLEGRA ALLERGY) is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenicity at doses up to 2-3 times the human dose. There are no adequate, well-controlled studies in pregnant women. First trimester: Limited data suggest no increased risk of major malformations. Second and third trimesters: No known specific fetal risks from antihistamine use; however, use only if clearly needed due to lack of extensive human data.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Fexofenadine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.24. Based on limited data, the relative infant dose is estimated to be less than 5% of the maternal weight-adjusted dose, which is considered low. However, caution is advised due to potential effects on the infant, such as drowsiness or irritability. Use only if clearly needed, and monitor the infant for adverse effects.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No specific dosing adjustments are recommended for fexofenadine during pregnancy, as pharmacokinetic data are limited. However, due to physiological changes in pregnancy (e.g., increased plasma volume, renal clearance), the standard adult dose (60 mg twice daily or 180 mg once daily) may require cautious use; consider lowest effective dose. No formal studies have been conducted to determine dose modifications.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Fexofenadine is a second-generation antihistamine with minimal CNS penetration, causing less sedation than first-generation agents. Onset of action is within 1 hour; peak effect at 2-3 hours. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) due to reduced clearance. Antacids containing aluminum or magnesium reduce absorption; separate by at least 2 hours. No significant QT prolongation at therapeutic doses.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take with water; do not take with fruit juices (apple, orange, grapefruit) as they reduce absorption.,Do not use with antacids containing aluminum or magnesium; wait at least 2 hours between doses.,May cause mild drowsiness in some patients; avoid driving if affected.,Do not exceed recommended dose; overdose may cause dizziness, drowsiness, or dry mouth.,Store at room temperature away from moisture and heat.,Consult healthcare provider if symptoms persist >7 days or if fever occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs ALLEGRA ALLERGY, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. ALLEGRA ALLERGY is a Antihistamine (Nonsedating) that works by Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine-induced vasodilation and bronchoconstriction by blocking the H1 receptor, thereby reducing allergic symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and ALLEGRA ALLERGY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of ALLEGRA ALLERGY is: Fexofenadine 180 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and ALLEGRA ALLERGY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. ALLEGRA ALLERGY is classified as Category C. Fexofenadine (ALLEGRA ALLERGY) is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenicity at doses up to 2-3 times the human dose. There are no adequate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.